HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 128,900 shares, a decline of 10.9% from the November 15th total of 144,700 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,020,000 shares, the short-interest ratio is currently 0.0 days.

HCW Biologics Price Performance

Shares of HCW Biologics stock traded down $0.01 on Tuesday, reaching $0.35. 196,678 shares of the stock were exchanged, compared to its average volume of 2,463,877. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.07 and a current ratio of 0.07. The firm has a market cap of $13.09 million, a PE ratio of -0.35 and a beta of 0.88. The firm’s 50 day moving average is $0.50 and its 200-day moving average is $0.60. HCW Biologics has a one year low of $0.28 and a one year high of $2.52.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.